Evaluation and Standardization of Ginseng and it's Components for Blood Pressure Regulation
NCT ID: NCT00728221
Last Updated: 2017-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
17 participants
INTERVENTIONAL
2007-11-30
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Evaluation and Standardization of Ginseng and Its Components for Blood Pressure Regulation
NCT00730951
Korean Red Ginseng Rg3 Extract on Arterial Stiffness and Blood Pressure
NCT01951443
Effect of Korean Red Ginseng on Central Blood Pressure in Patient With Essential Hypertension
NCT02211352
Effect of Korean Red Ginseng Extract on Blood Flow in Healthy Adults
NCT06236243
Blood Pressure Lowering Effect of Supplementation With Korea Red Ginseng Associated With Reductions in Circulating Lp-PLA2 Activity and Lysophospatidylcholines and an Increase in Dihydrobiopterin in Prehypertensive Subjects
NCT02326766
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Placebo capsules (3g)
Cornstarch
Placebo
2
Whole Korean Red Ginseng root (3g)
Korean Red Ginseng
Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.
Dosage form: whole root in capsules (3g)
3
Ginsenoside fraction of Korean Red Ginseng B (0.22g); bioequivalent to the original whole KRG root
Korean Red Ginseng (Panax ginseng)
Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.
Dosage form: total ginsenoside fraction in capsules
4
Polysaccharide fraction of KRG root (0.21g); bioequivalent to the original whole KRG root
Korean Red Ginseng (Panax Ginseng)
Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.
Dosage form: total polysaccharide fraction (panaxans) in capsules
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Korean Red Ginseng
Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.
Dosage form: whole root in capsules (3g)
Korean Red Ginseng (Panax ginseng)
Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.
Dosage form: total ginsenoside fraction in capsules
Cornstarch
Placebo
Korean Red Ginseng (Panax Ginseng)
Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.
Dosage form: total polysaccharide fraction (panaxans) in capsules
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy individuals (absence of major illnesses)
Exclusion Criteria
* Secondary hypertension (defined as SBP greater than 180mmHg and DBP greater than 110mmHg)
* Grade 3 hypertension (defined as SBP greater than 180mmHg and DBP greater than 110mmHg)
* Diabetes
* Chronic kidney disease
* Liver disease
* Estrogen-sensitive cancer
* Heavy alcohol use
* Bleeding disorders
* Planned surgery
* Angina
* CHF
* Coronary revascularization
* Peripheral vascular disease
* Coronary/cerebrovascular event in the last 6 months
* Prescriptions of MAO inhibitors, SSRIs, diuretics, sympathomimetics, herbal therapies, medication affecting nitric oxide synthesis, and/or anticoagulent medications within the last 6 months
* Sensitivity to any of the ingredients in the treatments or placebo
* Chronic use of or frequent prescriptions for NSAIDs
* Women of childbearing potential must not be pregnant or breast-feeding
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Heart and Stroke Foundation of Canada
OTHER
Unity Health Toronto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vladimir Vuksan, PhD
Role: PRINCIPAL_INVESTIGATOR
St. Michael's Hospital, University of Toronto
Alexandra Jenkins, PhD
Role: PRINCIPAL_INVESTIGATOR
Unity Health Toronto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Michael's Hospital Clinical Nutrition and Risk Factor Modification Centre
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jovanovski E, Peeva V, Sievenpiper JL, Jenkins AL, Desouza L, Rahelic D, Sung MK, Vuksan V. Modulation of endothelial function by Korean red ginseng (Panax ginseng C.A. Meyer) and its components in healthy individuals: a randomized controlled trial. Cardiovasc Ther. 2014 Aug;32(4):163-9. doi: 10.1111/1755-5922.12077.
Jovanovski E, Jenkins A, Dias AG, Peeva V, Sievenpiper J, Arnason JT, Rahelic D, Josse RG, Vuksan V. Effects of Korean red ginseng (Panax ginseng C.A. Mayer) and its isolated ginsenosides and polysaccharides on arterial stiffness in healthy individuals. Am J Hypertens. 2010 May;23(5):469-72. doi: 10.1038/ajh.2010.5. Epub 2010 Feb 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
118328
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.